Biomarkers- Advanced Technologies and Global Market (2009-2014)

Table of Contents

1. market overview

• 1.1. Defining biomarker
• 1.2. Defining the biomarker market
• 1.3. Biomarker and its applications- Holistic view with respect to diagnosis and drug discovery
• 1.4. Cardiovascular and cancer diagnosis applications have high priority in the existing and future market scenario
• 1.5. Biomarker Pre and Post clinical services impacting the biomarker services market
• 1.6. biomarker patent analysis

2. summary

3. biomarker market dynamics

• 3.1. Drivers
  • 3.1.1. high demand for biomarkers in drug discovery
  • 3.1.2. BIOMARKERs help in the Early detection of drug failures
  • 3.1.3. Biomarkers as cancer diagnostic tools
  • 3.1.4. Cro RECOGNIZE VALUE OF biomarkerS IN drug development
  • 3.1.5. Development in the life science fields such as proteomics and genomics enhances the biomarker applications
  • 3.1.6. Support from FDA for biomarker development
• 3.2. Restraints
  • 3.2.1. regulatory environment restrains the market growth
  • 3.2.2. High initial investment hinders biomarker applicability
  • 3.2.3. biomarker tests perceived to be unreliable
  • 3.2.4. disapproval of diagnotic tools for biomarkers hinders the market growth
  • 3.2.5. Biomarker validation approaches still not clearly addressed
  • 3.2.6. Lack of web based solutions for biomarker discovery
• 3.3. Opportunities
  • 3.3.1. Translational medicine focus on biomarker
  • 3.3.2. accurate and precise measures of diseases
  • 3.3.3. Commercial applications in proteomics

4. global biomarker tools market

• 4.1. Drivers:
  • 4.1.1. effective software solutions boost biomarker tools
  • 4.1.2. Discovery of cancer biomarkers
• 4.2. Pregenomic Biomarkers and Technologies
  • 4.2.1. Drivers
    • 4.2.1.1. Discovery of new biomarkers stimulates development of technologies
    • 4.2.1.2. Quick diagnosis offered by molecular diagnostics boosts the growth
  • 4.2.2. Molecular Diagnostics
  • 4.2.3. Drivers:
    • 4.2.3.1. Need for easy to handle and automated techniques drives the market
    • 4.2.3.2. Technological push supports the market growth
  • 4.2.4. Immunodiagnostics
  • 4.2.5. Drivers:
    • 4.2.5.1. Emerging applications of immunoassays supports immunodiagnostics market
    • 4.2.5.2. Need for timely diagnosis and early detection of diseases has spurred the growth
  • 4.2.6. Restraints
    • 4.2.6.1. Price erosion hinders the market growth
    • 4.2.6.2. Lack of standardization hampers market development
  • 4.2.7. Enzyme and Metabolite Assays
• 4.3. Postgenomic Biomarkers and Technologies
• 4.4. Drivers
  • 4.4.1. High demand for medical requirements boosts technological growth
  • 4.4.2. greater stress on individual risk assessment
• 4.5. Restraints
  • 4.5.1. High cost of genomics platform
  • 4.5.2. FDA approval poses a big challenge for market participants
• 4.6. Opportunities
  • 4.6.1. Emerging field of nutrition research to support the market growth
  • 4.6.2. Proteomics
  • 4.6.3. Drivers
    • 4.6.3.1. Need to enhance the efficiency and speed of drug discovery process
    • 4.6.3.2. Potential of proteomics in personalized therapy development
• 4.6.4. Restraints
  • 4.6.4.1. Expensive proteomics analysis tools leads to low adoption rates
  • 4.6.4.2. Technological need for speeding up validation process
• 4.6.5. Mass Spectrometry in Biomarker Discovery and Validation
• 4.6.6. Drivers
  • 4.6.6.1. Easy quantification of the protein structures created the need for mass spectrometry
  • 4.6.6.2. Rising popularity of integrated MS tools boosts the growth
• 4.6.7. Metabolomics
• 4.6.8. Drivers
  • 4.6.8.1. Emergence of Proteomics-sciences in the field of drug development spurs the market size.
  • 4.6.8.2. Rapid growth of metabolomics data analysis software and solution
• 4.6.9. 2D Gel Electrophoresis
• 4.6.10. Differential In-gel Electrophoresis
• 4.6.11. Transcriptomics
  • 4.6.11.1. Positional DNA Microarrays
  • 4.6.11.2. Encoded Particle Arrays
• 4.6.12. Analysis of Metabolites in Biological Specimens
  • 4.6.12.1. Disease-Related Biomarkers
  • 4.6.12.2. Metabolite Profiling for Biomarker Discovery
• 4.6.13. Imaging Biomarkers
• 4.6.14. Drivers
  • 4.6.14.1. Rising applications of imaging biomarkers in the drug development
  • 4.6.14.2. Success of imaging biomarkers in several diseases
  • 4.6.14.3. Molecular Imaging
  • 4.6.14.4. Magnetic Resonance Imaging
  • 4.6.14.5. Positron Emission Tomography
  • 4.6.14.6. FDG-PET Patient Phase I Studies
  • 4.6.14.7. Imaging Biomarkers as Study Endpoints
• 4.6.15. Others
  • 4.6.15.1. Bioinformatics
  • 4.6.15.2. Reagents

5. global biomarker services market

• 5.1. Drivers
  • 5.1.1. emergence of contract research organizations as service providers
  • 5.1.2. High ROI from investment in biomarker discovery by the PHARMACEUTICAL INDUSTRY
• 5.2. Biomarker Pre and Post Clinical Services
• 5.3. Drivers
  • 5.3.1. Biomarkers boost the efficiency in the drug discovery process.
  • 5.3.2. High duration and cost of the clinical trials drives the services
  • 5.3.3. Biomarker Testing
  • 5.3.4. Assay Development
• 5.4. Antibody Development
  • 5.4.1. Validation and Reporting
• 5.5. Sample Preparation
  • 5.5.1. Blood/biofluids
  • 5.5.2. Cell lines - eukaryotic and prokaryotic
  • 5.5.3. Frozen/RNAlater/RNAretain tissues
• 5.6. Other services
  • 5.6.1. Bioinformatics Services
  • 5.6.2. Data Analysis
  • 5.6.3. mRNA Analysis
• 5.7. miRNA Analysis
  • 5.7.1. miRNA Microarray Service
  • 5.7.2. miRNA Expression Profiling

6. global biomarker applications market

• 6.1. Drivers:
  • 6.1.1. Demand for early predictive technologies into pre-clinical and early clinical development phase
  • 6.1.2. Developments in high-throughput technologies, systems biology and bioinformatics
  • 6.1.3. Development of safer drugs with increased therapeutic efficacy in a cost-effective manner
  • 6.1.4. Less expense of genetic biomarkers incorporated for genotyping boosting the demand for the same.
• 6.2. Restraints:
  • 6.2.1. Biomarker without clinical validation generates erroneous end points
  • 6.2.2. Large varieties of biomarkers delay evaluation, clinically
  • 6.2.3. Uncertainties in Pharmacogenomics Testing Hinders Market Adoption
  • 6.2.4. Ethical Issues regarding Patient' s Confidentiality and Rights Pose another Area of concern.
• 6.3. Diagnosis
  • 6.3.1. Cancer Diagnosis
• 6.4. Market Drivers:
  • 6.4.1. Adoption of biomarker for cancer diagnosis
  • 6.4.2. Current development and research driving the biomarker market for cancer diagnosis.
    • 6.4.2.1. Ovarian Cancer Diagnostics
    • 6.4.2.2. HER2 Breast cancer Diagnostics
    • 6.4.2.3. Bladder Cancer
    • 6.4.2.4. Cervical Cancer Diagnostics
    • 6.4.2.5. Prostate Cancer
  • 6.4.3. Cardiovascular and Metabolic Diseases:
• 6.5. Market Drivers:
  • 6.5.1. Cardiovascular Biomarkers potential to accurately detect heart failure.
  • 6.5.2. Biomarkers facilitate enhanced diagnosing and managing metabolic disease
• 6.6. Restraints
  • 6.6.1. Specific technical requirements are unmet
  • 6.6.2. Autoimmune disease and inflammatory diseases
• 6.7. Drivers
  • 6.7.1. Need for effective treatment and diagnosis
• 6.8. Restraints
  • 6.8.1. Lack of understanding of the disease cause among researchers and scientists.
  • 6.8.2. Neurological Diseases:
• 6.9. Drivers
  • 6.9.1. Patients demand for rapid diagnosis and treatment
  • 6.9.2. Precaution and effective clinical diagnosis for autoimmune diseases
• 6.10. Restraints
  • 6.10.1. Limitations in the reimbursement systems
  • 6.10.2. The costs for diagnostics are starting to be offset against the savings in other areas
    • 6.10.2.1. Alzheimer' s disease
      • 6.10.2.1.1. Image based biomarkers
      • 6.10.2.1.2. Genetic Markers
      • 6.10.2.1.3. Biomarkers in blood:
      • 6.10.2.1.4. Biomarkers in cerebrospinal fluid
    • 6.10.2.2. Schizophrenia:
    • 6.10.2.3. Parkinson' s disease:
• 6.10.3. Tuberculosis:
• 6.11. Market DRiver
  • 6.11.1. Biomarkers ability to accelerate and streamline drug development for tuberculosis.
  • 6.11.2. Rise in the drug resistant tuberculosis
    • 6.11.2.1. Stroke Diagnosis
• 6.12. Driver
  • 6.12.1. Rising incidence of stroke globally has boosted the need for biomarkers
  • 6.12.2. Transition in dietary intake globally
• 6.13. Drug Development & Discovery
  • 6.13.1. Drug Targets
    • 6.13.1.1. Target Validation
      • 6.13.1.1.1. Target Discovery
    • 6.13.1.2. Target Discovery Using Functional Genomics
  • 6.13.2. ADME-TOX profiling
  • 6.13.3. Drug development and process quality assurance

7. ographical analysis of biomarker market

• 7.1. north america:
• 7.2. Europe:
• 7.3. Asia:
• 7.4. row:

8. competitive landscape

9. company profiles

• 9.1. Affymetrix
• 9.2. Agilent Technologies
• 9.3. Amgen
• 9.4. Ariadne
• 9.5. Banyan Biomarkers Inc.
• 9.6. BG Medicine
• 9.7. Biophysical Corp
• 9.8. BioSystems International (BSI)
• 9.9. Calibrant
• 9.10. Caprion Proteomics
• 9.11. Correlogic Systems Inc
• 9.12. Cyclacel
• 9.13. deCODE
• 9.14. Epigenomics
• 9.15. Exagen Diagnostics Inc.
• 9.16. GE Healthcare
• 9.17. Genedata
• 9.18. GeneGo
• 9.19. GeneNews
• 9.20. Gyros AB
• 9.21. Human Metabolome Technologies (HMT)
• 9.22. Illumina Inc
• 9.23. Imgenex
• 9.24. InforSense
• 9.25. Ingenuity Systems
• 9.26. Insilicos
• 9.27. Integromics
• 9.28. MDS Inc
• 9.29. Metabolon Inc
• 9.30. Metanomics Health GmBH
• 9.31. MicroDiscovery
• 9.32. Molecular Connections
• 9.33. Nanogen
• 9.34. NextGen Group PLC
• 9.35. Nonlinear USA Inc
• 9.36. Nuvera Biosciences
• 9.37. Ocimum Biosolutions
• 9.38. Pam Gene BV
• 9.39. Partek
• 9.40. Pronota
• 9.41. Perlegen
• 9.42. Phenomenome Discoveries Inc
• 9.43. Siemens Healthcare
• 9.44. Singulex
• 9.45. Softgenetics llc
• 9.46. Tyrian
• 9.47. Zeptosens
• 9.48. Patents for united states
• 9.49. Patents for europe
• 9.50. Patents for japan

LIST OF TABLES

• SUMMARY TABLE Global biomarker market BY tools and services 2009 - 2014 ($ thousands)
• Table 1 Global Bio marker Tools market by Product 2007-2014 ($ thousands)
• Table 2 Global Bio marker Tools market by Geography 2007-2014 ($ thousands)
• Table 3 Global Pregenomic Biomarkers and Technologies market by Product 2007-2014 ($ thousands)
• Table 4 Global Pregenomic Biomarkers and Technologies market by Geography 2007-2014 ($ thousands)
• Table 5 Global Molecular Diagnostics market by Product 2007-2014 ($ thousands)
• Table 6 Global Molecular Diagnostics market byGeography 2007-2014 ($ thousands)
• Table 7 Global Immunodiagnostics market by Geography 2007-2014 ($ thousands)
• Table 8 Global Enzyme and Metabolite Assays market byGeography 2007-2014 ($ thousands)
• Table 9 Global Post genomic Bio markers and Technologies market by Product 2007-2014 ($ thousands)
• Table 10 Global Post genomic Bio markers and Technologies market by Geography 2007-2014 ($ thousands)
• Table 11 Global Proteomics market by Product 2007-2014 ($ thousands)
• Table 12 Global Proteomics market by Geography 2007-2014 ($ thousands)
• Table 13 Global Mass Spectrometry in Bio marker Discovery and Validation market by Geography 2007-2014 ($ thousands)
• Table 14 Global Metabolomics market by Geography 2007-2014 ($ thousands)
• Table 15 Global 2D Gel Electrophoresis market by Geography 2007-2014 ($ thousands)
• Table 16 Global Differential In-gel Electrophoresis market by Geography 2007-2014 ($ thousands)
• Table 17 Global Transcriptomics market by Product 2007-2014 ($ thousands)
• Table 18 Global Transcriptomics market by Geography 2007-2014 ($ thousands)
• Table 19 Global Positional DNA Microarrays market by Geography 2007-2014 ($ thousands)
• Table 20 Global Encoded Particle Arrays market by Geography 2007-2014 ($ thousands)
• Table 21 Global Analysis of Metabolites in Biological Specimens market by Product 2007-2014 ($ thousands)
• Table 22 Global Analysis of Metabolites in Biological Specimens market by Geography 2007-2014 ($ thousands)
• Table 23 Global Disease-Related Biomarkers market byGeography 2007-2014 ($ thousands)
• Table 24 Global Metabolite Profiling for Bio marker Discovery market by Geography 2007-2014 ($ thousands)
• Table 25 Global Imaging Biomarkers market by Product 2007-2014 ($ thousands)
• Table 26 Global Imaging Biomarkers market by Geography 2007-2014 ($ thousands)
• Table 27 Global Molecular Imaging market by Geography 2007-2014 ($ thousands)
• Table 28 Global Magnetic Resonance Imaging market by Geography 2007-2014 ($ thousands)
• Table 29 Global Positron Emission Tomography market by Geography 2007-2014 ($ thousands)
• Table 30 Global FDG-PET Patient Phase I Studies market by Geography 2007-2014 ($ thousands)
• Table 31 Global Imaging Bio markers as Study Endpoints market by Geography 2007-2014 ($ thousands)
• Table 32 Global Others market by Product 2007-2014 ($ thousands)
• Table 33 Global Others market by Geography 2007-2014 ($ thousands)
• Table 34 Global Bioinformatics market by Geography 20072014 ($ thousands)
• Table 35 Global Reagents market by Geography 2007-2014 ($ thousands)
• Table 36 Global Biomarker Services market by Product 2007-2014 ($ thousands)
• Table 37 Global Bio marker Services market by Geography 2007-2014 ($ thousands)
• Table 38 Global Biomarker Pre and Post Clinical Services market by product 2007-2014 ($ thousands)
• Table 39 Global Biomarker Pre and Post Clinical Services market by Geography 2007-2014 ($ thousands)
• Table 40 Global Biomarker Testing market by Geography 2007-2014 ($ thousands)
• Table 41 Global Assay Development market by Geography 2007-2014 ($ thousands)
• Table 42 Global Antibody Development market by Geography 2007-2014 ($ thousands)
• Table 43 Global Validation and Reporting market by Geography 2007-2014 ($ thousands)
• Table 44 Global Sample Preparation market by Product 2007-2014 ($ thousands)
• Table 45 Global Sample Preparation market by Geography 2007-2014 ($ thousands)
• Table 46 Global Blood/bio fluids market by Geography 200 - 2014 ($ thousands)
• Table 47 Global Cell lines - eukaryotic and prokaryotic market by Geography 200 - 2014 ($ thousands)
• Table 48 Global Frozen/RNAlater/RNAretain tissues marketby Geography 2007-2014 ($ thousands)
• Table 49 Global other services market by product 2007-2014 ($ thousands)
• Table 50 Global other services market by geography 2007-2014 ($ thousands)
• Table 51 Global bioinformatics services market BY GEOGRAPHY 2007-2014 ($ thousands)
• Table 52 Global data analysis market by geography 2007-2014 ($ thousands)
• Table 53 Global mrna analysis market by geography 2007-2014($ thousands)
• Table 54 Global mirna analysis market by product 2007-2014 ($ thousands)
• Table 55 Global mirna analysis market by geography 2007-2014 ($ thousands)
• Table 56 Global mirna microarray service market by geography 2007-2014 ($ thousands)
• Table 57 Global miRNA expresion profiling market by geography 2007-2014 ($ thousands)
• Table 58 Global biomarker applications market 2007-2014 ($ thousands)
• Table 59 Global diagnosis market by product 2007-2014 ($ thousands)
• Table 60 Global cancer diagnosis market by product 2007-2014 ($ thousands)
• Table 61 Global neurological disease market by product 2007-2014 ($ thousands)
• Table 62 Global alzheimer' s disease market by product 2007-2014 ($ thousands)
• Table 63 Global drug development and discovery market by product 2007-2014 ($ thousands)
• Table 64 Global drug target market by product 2007-2014 ($ thousands)
• Table 65 Global target validation market by product 2007-2014 ($ thousands)
• TABLE 66 NORTH AMERICAn BIOmarker MARKET 2007-2014 ($ thousands)
• TABLE 67 european BIOmarker MARKET 2007-2014 ($ thousands)
• TABLE 68 asian BIOmarker MARKET 2007-2014 ($ thousands)
• TABLE 69 row BIOmarker MARKET 2007-2014 ($ thousands)
• table 70 NEW PRODUCT, TECHNOLOGY, SERVICE LAUNCH (2008-2009)
• table 71 list of agreements and collaborations (2008-2009)

LIST OF FIGURES

• Figure 1 biomarker discovery
• figure 2 evolution of biomarkers and future shift Defining the biomarker market
• Figure 3 Biomarker market segmentation
• figure 4 Business architecture
• figure 5 biomarker opportunity
• figure 6 biomarker challenges
• figure 7 biomarker applications market prospective
• Figure 8 Biomarker applications market dynamics
• Figure 9 Biomarker services markeT dynamics
• figure 10 patent analysis by technology 2006 to 2008
• figure 11 Patent analysis by competitors (2004-2008)
• figure 12 patent analysis by geography
• Figure 13 Biomarker clinical trial effectiveness
• Figure 14 Biomarker applications in molecular diagnostics
• Figure 15 imaging biomarkers APPLICATIONS in drug development
• Figure 16 Common bioinformatics microarrays for biomarker discovery
• Figure 17 Biomarker areas in drug development process
• Figure 18 Global biomarker market by geography
• Figure 19 Global biomarker tools market by geography
• Figure 20 Global biomarker service market by geography
• figure 21 geography wise biomarker market- global perspective
• figure 22 Major segments focused by global biomarker players
• Figure 23 Competitive landscape for strategy formation (2008-2009)